Navigation Links
Medication appears well-tolerated, beneficial in Huntington's disease patients
Date:2/8/2010

A medication previously studied in patients with Alzheimer's disease (latrepirdine) appears well tolerated and may improve thinking, learning and memory skills among individuals with Huntington's disease, according to a report in the February issue of Archives of Neurology, one of the JAMA/Archives journals.

"Huntington's disease is a hereditary neurodegenerative disorder that affects movement, behavior and cognition and leads to death within 20 years of disease onset," the authors write as background information in the article. "Cognitive [thinking, learning and memory] impairment occurs early in the disease and deteriorates as Huntington's disease progresses, contributing to loss of ability to work and perform activities of daily living." The only approved therapy for Huntington's disease, tetrabenazine, treats only motor symptoms and does not alter the course of the disease or prevent cognitive decline.

Abnormalities in mitochondria, parts of cells that help convert food into energy, have been implicated in the development of Huntington's disease. The synthetic molecule latrepirdine stabilizes and improves mitochondrial function, and has been studied as a way to improve cognitive, behavioral and functional outcomes in patients with Alzheimer's disease. Karl Kieburtz, M.D., M.P.H., of the School of Medicine and Dentistry, University of Rochester, N.Y., and colleagues assessed the safety and tolerability of latrepirdine among 91 participants with mild to moderate Huntington's disease at enrollment (2007 to 2008).

For 90 days, 46 patients were randomly assigned to take 20 milligrams of latrepirdine three times daily and the other 45 took a matching placebo. The medication was well tolerated (87 percent of the patients given latrepirdine completed the study, compared with 82 percent in the control group) and adverse event rates were similar between the two groups (70 percent in the treatment group vs. 80 percent in the placebo group).

In addition, the treatment resulting in improved average scores on an evaluation measuring overall cognitive function. Scores of individuals in the placebo group remained steady over the study period.

"Taken together, our data suggest that latrepirdine, at a dosage of 20 milligrams three times daily, is well tolerated for 90 days in patients with Huntington's disease and may have a beneficial effect on cognition," the authors conclude. "Future studies of latrepirdine are planned to further evaluate the effect of latrepirdine on the cognitive and behavioral symptoms of Huntington's disease."


'/>"/>

Contact: Abena Foreman-Trice
abena@virginia.edu
434-243-2734
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
2. Manic phase of bipolar disorder benefits from breast cancer medication
3. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
4. Mayo Clinic study indicates medication for ADHD may help student outcomes
5. Diet and medications may assist prevention of prostate cancer
6. Delmarva Foundation Implements Medication Therapy Management Program in Maryland and DC
7. Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors
8. Moses Taylor Hospital Automates Medication Reconciliation
9. Cautious Optimism for New Alzheimers Medications, Reports the Harvard Mental Health Letter
10. Patients cant recall their medications to tell doctors
11. Patient Empowerment -- Medication Error
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology: